Inovio Pharmaceuticals and the Coalition for Epidemic Preparedness Innovations (CEPI) have dosed subjects in a Phase I clinical trial of the former’s DNA candidate vaccine, INO-4500, to prevent infection from the Lassa virus.

Inovio plans to enrol about 60 volunteers to evaluate the safety, tolerability and immune responses of INO-4500.

The first-in-human, placebo-controlled, blinded, dose-escalation trial, as well as its INO-4500 programme, is fully funded through a global partnership with CEPI.

CEPI Vaccine Development director Melanie Saville said: “With marked increases in the number of cases documented in Nigeria over the last two years and outbreaks occurring annually, Lassa fever remains a serious public health threat across West Africa.”

Inovio plans to use these study results and expects to advance its Lassa candidate vaccine into a Phase II field trial in endemic countries of West Africa later this year and next year.

Inovio president and CEO Dr Joseph Kim said: “Inovio’s class-leading synthetic nucleic vaccines delivered intradermally with its proprietary Cellectra efficacy enhancing systems are well suited to rapidly produce countermeasures against emerging viral threats potentially protecting large populations from a pandemic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Inovio has rapidly advanced several global health candidate vaccines, including those against HIV, Ebola, MERS, and Zika, and has reported above 90% immune response rates from multiple clinical studies. We join our partner CEPI in the shared quest to bring new vaccines to medicine and save lives.”

Last year, Inovio received a $56m grant from CEPI to develop vaccine candidates through Phase II against Lassa fever and Middle East Respiratory Syndrome (MERS).